The Angel Lab conducts basic science and translational research to investigate mechanisms of immune dysfunction during HIV infection, and evaluates the effects of antiretroviral, immune-mediated, or oncolytic virus-based treatments as potential approaches to a cure for HIV. Our research is led by Dr. Jonathan Angel, a clinician scientist and Infectious Diseases specialist, who has played leadership roles on investigator-lead clinical studies, the Canadian HIV Cure Enterprise (CanCURE), and the CIHR Pan-Canadian Network for HIV and STBBI Clinical Trials Research.

- N. Ranganath, T.S. Sandstrom, S.C. Burke Schinkel, S.C. Cote, J.B. Angel. “The Oncolytic Virus MG1 Targets and Eliminates Cells Latently Infected with HIV-1: Implications for an HIV Cure.” J Infect Dis. 217(5):721-730, Feb 2018.

- T.S. Sandstrom, N. Ranganath, S.C. Burke Schinkel, S. Salahuddin, O. Meziane, S.C. Coté, C. Costiniuk, M-A. Jenabian, J.B. Angel. “HIV-Infected Macrophages Are Infected and Killed by the Interferon-Sensitive Rhabdovirus MG1.” J. Virol. 95(9):e01953-20, Apr 2021.

- A. Vera-Cruz, N. Tanphaichitr, J.B. Angel. “Antimicrobial Peptide, LL-37, and its Potential as an Anti-HIV Agent.” Clin Invest Med. 44(3):E64-71, Oct 2021.

- B. Molyer, A. Kumar, J.B. Angel. “SMAC Mimetics as Therapeutic Agents in HIV infection.” Front Immunol. 12:780400, Nov 2021.

- S.G. Lee, W. Kiattiburut, S.C. Burke Schinkel, J.B. Angel, N. Tanphaichitr. "Safety of multiple administrations of spermicidal LL-37 antimicrobial peptide into the mouse female reproductive tract." Mol Hum Reprod. 2023 Jun 30;29(7):gaad023, June 2023.